Evaluating drug sensitivity in organoids from breast cancer patients with fluid buildup

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to recruit 90 patients diagnosed with metastatic breast cancer who also have hydrothorax and ascitic fluid. It will collect baseline medical data and tumor samples from these patients to create patient-derived organoids (PDOs). The PDOs will be tested with standard chemotherapy drugs to assess their drug sensitivity, and the results will be correlated with actual clinical outcomes using RECIST criteria. This approach seeks to personalize treatment plans and improve the efficacy of therapies for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed informed consent form and willingness to participate in the clinical study.
2. patients aged between 18 and 70 years old.
3. Confirmed metastatic breast cancer patients with hydrothorax and ascite fluid, which was verified to contain tumor cells by lab.
4. ECOG performance status score of 0-1.
5. No significant abnormalities in liver and kidney function (BIL \<1.5-fold upper limit of normal (ULN)；ALT\<2.5×ULN; AST\<2.5×ULN；Crea≤1×ULN).

Exclusion Criteria:

1.Patients not suitable for chemotherapy and target therapy

Where it's running

• Second affiliated hospital of zhejiang university
  Hangzhou, Zhejiang, China Recruiting
• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting
• 2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Zhigang Chen, Md
• Email: chenzg@zju.edu.cn
• Phone: +8657189713716

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Decision Support Tool for People with Advanced Breast Cancer

  This study tests a decision support tool called COAST to help people with stage IV breast cancer talk with their doctors and share treatment preferences.

  Recruiting at 3 sites Weill Medical College of Cornell University · Brooklyn, New York and 2 other locations · NCT07635147

• Gut leakage in dengue: is the intestinal barrier affected during infection?

  Researchers are studying whether dengue infection disrupts the gut barrier and if that contributes to severe disease in adults with dengue who are in hospital.

  Recruiting University of Oxford · Chittagong, Chattogram Division · NCT07602920

• HER2-PET to Predict T-DXd Benefit in Advanced Breast Cancer

  This study tests whether HER2-PET imaging can help predict how well T-DXd will work for adults with advanced HER2-positive or HER2-low breast cancer receiving the drug.

  Recruiting Fudan University · Shanghai · NCT07586215

• Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis

  This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.

  Recruiting Phase 4 Asian Institute Of Medical Sciences · Hyderābād, Sindh · NCT07521332

• Intraperitoneal SK-NK cell infusion for advanced ovarian cancer with massive ascites

  This will try giving highly activated donor NK cells directly into the abdomen once weekly for four weeks to see if it helps people with advanced ovarian cancer who have large-volume malignant ascites and no standard treatment options.

  Recruiting Phase 1/2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07435701

• VIATORR TIPS 6–10 mm: Real-world use in cirrhosis with portal hypertension

  A real-world registry is seeing how the GORE VIATORR TIPS Endoprosthesis with Controlled Expansion 6-10 mm works over 2 years in adults with cirrhosis and portal hypertension.

  Recruiting at 5 sites W.L.Gore & Associates · Atlanta, Georgia and 4 other locations · NCT07390344

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.